Literature DB >> 34323284

TGF-β links glycolysis and immunosuppression in glioblastoma.

Lingli Gong1, Li Ji1, Daxing Xu1, Jingjing Wang1, Jian Zou2.   

Abstract

Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, characterized by diffuse infiltration, dysplasia, and resistance to therapy. Metabolic remodeling and immunosuppression are typical events which contribute to GBM progression, but the molecular link between these two events remains largely undetermined. Studies have shown that high levels of transforming growth factor-β (TGF-β) and its receptors are associated with glioma malignancy and a poor prognosis. TGF-β plays an important role in cell metabolism and immunity. During tumorigenesis, TGF-β induces a shift in cell metabolism from oxidative phosphorylation to aerobic glycolysis, providing a favorable environment for tumor growth. Locally, TGF-β creates an immunosuppressive microenvironment and promotes the malignant phenotype of GBM. In this review, we aim to link GBM aerobic glycolysis and immunosuppression through TGF-β to provide new ideas for the study of GBM.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34323284     DOI: 10.14670/HH-18-366

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  141 in total

Review 1.  Transforming growth factor-β signaling: Tumorigenesis and targeting for cancer therapy.

Authors:  Amirhossein Ahmadi; Masoud Najafi; Bagher Farhood; Keywan Mortezaee
Journal:  J Cell Physiol       Date:  2018-12-07       Impact factor: 6.384

Review 2.  Heterogeneity maintenance in glioblastoma: a social network.

Authors:  Rudy Bonavia; Maria-del-Mar Inda; Webster K Cavenee; Frank B Furnari
Journal:  Cancer Res       Date:  2011-05-31       Impact factor: 12.701

Review 3.  Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.

Authors:  Sameer Agnihotri; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2015-07-14       Impact factor: 12.300

4.  Stimulation of glycolysis and amino acid uptake in NRK-49F cells by transforming growth factor beta and epidermal growth factor.

Authors:  P Boerner; R J Resnick; E Racker
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 5.  Metabolic heterogeneity and adaptability in brain tumors.

Authors:  Christian E Badr; Daniel J Silver; Florian A Siebzehnrubl; Loic P Deleyrolle
Journal:  Cell Mol Life Sci       Date:  2020-06-06       Impact factor: 9.261

6.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

7.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

8.  Transforming growth factor beta 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription.

Authors:  M G Alexandrow; H L Moses
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

Review 9.  Transforming growth factor β and bone morphogenetic protein actions in brain tumors.

Authors:  Laia Caja; Claudia Bellomo; Aristidis Moustakas
Journal:  FEBS Lett       Date:  2015-05-06       Impact factor: 4.124

10.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.

Authors:  U Bogdahn; P Hau; G Stockhammer; N K Venkataramana; A K Mahapatra; A Suri; A Balasubramaniam; S Nair; V Oliushine; V Parfenov; I Poverennova; M Zaaroor; P Jachimczak; S Ludwig; S Schmaus; H Heinrichs; K-H Schlingensiepen
Journal:  Neuro Oncol       Date:  2010-10-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.